AlloSure™ Shows Promise to Detect Rejection in Transplant Patients with a Simple Blood Test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Piper Jaffray Remains Bullish on CareDx (CDNA) Following Presentation of AlloSure Performance
June 14, 2016 9:07 AM EDTPiper Jaffray maintained an Overweight rating and $6.00 price target on CareDx, Inc (NASDAQ: CDNA) following the company's presentation of its DART clinical trial. Piper Jaffray would describe DART's first look data as solid with AlloSure a significantly better predictor of kidney health than creatinine.
Analyst William Quirk... More
Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition
June 14, 2016 7:20 AM EDTMizuho Securities maintained a Buy rating on CareDx, Inc (NASDAQ: CDNA), and cut the price target to $8.00 (from $12.00) mainly due to share dilution from the Allenex acquisition. The deal transforms CDNA into a comprehensive transplant test provider, adding pre-transplant solutions, and increases the... More
